| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.06 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.071 | 0.06 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.06 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.1 | 0.06 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.063 | 0.06 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.07 | 0.06 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | 0.065 | 0.06 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.064 | 0.06 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.06 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.07 | 0.06 |